Literature DB >> 15937876

Neuropathology of paraneoplastic neuropathy with anti-disialosyl antibody.

Michio Kobayashi1, Kazumaro Kato, Kei Funakoshi, Sumio Watanabe, Itaru Toyoshima.   

Abstract

We report a paraneoplastic neuropathy with severe motor involvement following sensory-ataxic disturbance. Anti-disialosyl immunoglobulin M (IgM) antibody was detected in the course of malignant lymphoma of diffuse large B-cell type, which usually spares the motor system. Onset was subacute, with relapsing and remitting sensory ataxia, muscle weakness, bulbar palsy, respiratory paralysis, and ophthalmoplegia; only neck rotation was retained in the terminal stage. Autopsy showed no lymphoma cells infiltrating the nervous system. Motor neurons survived in the spinal cord, but mean diameter of the ventral spinal nerve roots was reduced considerably. The gracile fasciculus and the sural nerve were more markedly degenerated than proximal portions. Morphometric study showed that most of the proximal motor and sensory axons did not extend distally. This autopsy report provides further definition of a neuropathy associated with malignant lymphoma and IgM antibodies against disialosyl residues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937876     DOI: 10.1002/mus.20361

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

Review 1.  Neurologic complications of non-Hodgkin's lymphoma.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

Review 2.  Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas.

Authors:  Francesc Graus; Helena Ariño; Josep Dalmau
Journal:  Blood       Date:  2014-04-04       Impact factor: 22.113

3.  Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report.

Authors:  Weina Ju; Baochang Qi; Xu Wang; Yu Yang
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.